These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30644389)

  • 1. Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation.
    Kano Y; Gebregiworgis T; Marshall CB; Radulovich N; Poon BPK; St-Germain J; Cook JD; Valencia-Sama I; Grant BMM; Herrera SG; Miao J; Raught B; Irwin MS; Lee JE; Yeh JJ; Zhang ZY; Tsao MS; Ikura M; Ohh M
    Nat Commun; 2019 Jan; 10(1):224. PubMed ID: 30644389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
    Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
    Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors.
    Gebregiworgis T; Kano Y; St-Germain J; Radulovich N; Udaskin ML; Mentes A; Huang R; Poon BPK; He W; Valencia-Sama I; Robinson CM; Huestis M; Miao J; Yeh JJ; Zhang ZY; Irwin MS; Lee JE; Tsao MS; Raught B; Marshall CB; Ohh M; Ikura M
    Nat Commun; 2021 Nov; 12(1):6274. PubMed ID: 34725361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
    Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
    Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
    Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
    Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
    Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
    Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
    Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
    Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
    [No Abstract]   [Full Text] [Related]  

  • 8. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
    Jiang L; Xu W; Chen Y; Zhang Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis.
    Bunda S; Burrell K; Heir P; Zeng L; Alamsahebpour A; Kano Y; Raught B; Zhang ZY; Zadeh G; Ohh M
    Nat Commun; 2015 Nov; 6():8859. PubMed ID: 26617336
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
    Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling.
    Fedele C; Li S; Teng KW; Foster CJR; Peng D; Ran H; Mita P; Geer MJ; Hattori T; Koide A; Wang Y; Tang KH; Leinwand J; Wang W; Diskin B; Deng J; Chen T; Dolgalev I; Ozerdem U; Miller G; Koide S; Wong KK; Neel BG
    J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33045063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sprouty2-modulated Kras signaling rescues Shp2 deficiency during lens and lacrimal gland development.
    Pan Y; Carbe C; Powers A; Feng GS; Zhang X
    Development; 2010 Apr; 137(7):1085-93. PubMed ID: 20215346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 mediates clinical resistance to the KRAS
    Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
    Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop.
    Fujimura K; Wang H; Watson F; Klemke RL
    Cancer Res; 2018 Mar; 78(6):1444-1456. PubMed ID: 29321164
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Nelson AC; Turbyville TJ; Dharmaiah S; Rigby M; Yang R; Wang TY; Columbus J; Stephens R; Taylor T; Sciacca D; Onsongo G; Sarver A; Subramanian S; Nissley DV; Simanshu DK; Lou E
    J Biol Chem; 2020 Jul; 295(28):9335-9348. PubMed ID: 32393580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancers.
    Miao Y; Bai Y; Miao J; Murray AA; Lin J; Dong J; Qu Z; Zhang RY; Nguyen QD; Wang S; Yu J; Nguele Meke F; Zhang ZY
    J Clin Invest; 2024 Jun; 134(15):. PubMed ID: 38842946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types.
    Vazhappilly CG; Saleh E; Ramadan W; Menon V; Al-Azawi AM; Tarazi H; Abdu-Allah H; El-Shorbagi AN; El-Awady R
    Invest New Drugs; 2019 Apr; 37(2):252-261. PubMed ID: 29947013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity.
    Zheng W; Yang Z; Song P; Sun Y; Liu P; Yue L; Lv K; Wang X; Shen Y; Si J; Zhang X; Ke Y; Cheng H; Hu W
    Cancer Lett; 2023 Feb; 555():216029. PubMed ID: 36493900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors.
    Sahu P; Mitra A; Ganguly A
    Int Rev Cell Mol Biol; 2024; 386():167-222. PubMed ID: 38782499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.